Ramipril Patent Expiration
Ramipril is Used for reducing the risk of myocardial infarction, stroke, and death. It was first introduced by King Pharmaceuticals Llc
Ramipril Patents
Given below is the list of patents protecting Ramipril, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vostally | US12343338 | Ramipril Solution For Oral Dosage | Aug 16, 2039 | Rosemont Pharms |
| Altace | US7368469 | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
Aug 30, 2020
(Expired) | King Pfizer |
| Altace | US7368469 | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
Aug 30, 2020
(Expired) | King Pharms Llc |
Ramipril's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ramipril:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction | John Paul II Hospital, Krakow | NA |
RECRUITING
(Jul 1, 2026)
| PHASE3 |